Compare VVX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | XERS |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2014 | 2021 |
| Metric | VVX | XERS |
|---|---|---|
| Price | $80.27 | $16.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $90.27 | $17.29 |
| AVG Volume (30 Days) | 324.3K | ★ 3.2M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | 100.00 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $4,480,038,000.00 | $49,590,000.00 |
| Revenue This Year | $12.52 | $37.58 |
| Revenue Next Year | $4.83 | $31.16 |
| P/E Ratio | $33.58 | ★ N/A |
| Revenue Growth | 3.65 | ★ 142.67 |
| 52 Week Low | $50.89 | $5.25 |
| 52 Week High | $93.98 | $16.88 |
| Indicator | VVX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 82.90 |
| Support Level | $65.25 | $5.90 |
| Resistance Level | $84.39 | N/A |
| Average True Range (ATR) | 3.72 | 0.66 |
| MACD | 0.32 | 0.56 |
| Stochastic Oscillator | 66.79 | 93.75 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.